Source - RNS
RNS Number : 8368J
e-Therapeutics plc
14 September 2016

e-Therapeutics plc

('e-Therapeutics' or 'the Company')


Management Update


Oxford, UK, 14 September 2016 - e-Therapeutics plc (AIM :ETX) announces that following its full year results statement on 22 March 2016 which highlighted the Company's strategic refocus on its discovery platform, Steve Self will stand down as Development Director and leave the Company on 30 September 2016. 


Iain Ross, Executive Chairmen, commented: "Steve joined e-Therapeutics in December 2010 following a distinguished career at The Wellcome Foundation, Boots Healthcare and as R&D Director of Merck's Generic Global business. We thank him for his significant contribution to our activities and wish him continuing success in his new endeavours."






e-Therapeutics plc

Iain Ross, Chairman

Steve Medlicott, Finance Director


Tel: +44 (0) 1993 883 125 


Numis Securities Limited

Michael Meade / Freddie Barnfield (Corporate Finance)

James Black (Corporate Broking)


Tel: +44 (0) 207 260 1000


Instinctif Partners

Melanie Toyne Sewell / Jayne Crook

Tel: +44 (0) 207 457 2020

Email: [email protected]



About e-Therapeutics plc


e-Therapeutics (AIM: ETX) is a drug discovery company with a proprietary discovery platform based on advances in network pharmacology and chemical biology.


 The Company is applying its platform to the discovery of new drug candidates. The therapeutic focus of the Company's activity is in immuno-oncology, addressing drug resistance in targeted cancer therapies and anti-infectives. The platform is highly productive, yielding multiple potent and selective molecules at a much higher rate and more quickly than is reported for conventional drug discovery. 


e-Therapeutics has a variety of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNFα; ETS2400, Hedgehog pathway inhibition and ETS5200, broad spectrum antivirals. The Company has recently completed a phase IIb clinical trial for ETS6103, a drug to treat major depressive disorder.  


The Company is fully funded to advance its drug discovery programmes. It is based in Oxford and Newcastle, UK. For more information, visit  

This information is provided by RNS
The company news service from the London Stock Exchange